title: Highly urgent liver transplantation: possible impact of donor-recipient ABO matching on the outcome after transplantation.
abstract: BACKGROUND
  Survival after liver transplantation for fulminant hepatic failure has been reported to be less favorable than survival for patients with chronic liver diseases.
  
  
  METHODS
  We have studied all patients (n=229) undergoing highly urgent liver transplantation from 1990 to 2001 in the Nordic countries. The impact of patient and donor characteristics, with emphasis on donor-recipient ABO matching (identical, compatible, incompatible), has been studied.
  
  
  RESULTS
  One-year and 3-year patient survival rates were 73% and 70% for the total period and 86% and 78% for the last 4-year period. Patients receiving an ABO-compatible liver allograft had significantly lower patient survival rates than those receiving an ABO-identical donor organ (1-year patient survival rates 66% of vs. 79%, P=0.03). Graft survival rates varied less (1-year graft survival rates of 64% vs. 74%, P=0.09). Patients receiving an ABO-incompatible liver allograft had patient survival rates of 70% at 1 year and 60% at 3 years but low graft survival rates (40% and 30% at 1 and 3 years). In a multiple regression analysis, significant independent predictors of poor patient survival were early year of transplantation, ABO-compatible donor, high donor age, and waiting time more than 3 days and less than 9 days.
  
  
  CONCLUSIONS
  Survival after highly urgent liver transplantation has improved and is comparable to that observed in patients receiving a liver allograft because of chronic liver disease. Patients receiving an ABO-identical donor organ had significantly higher patient survival rates compared with those receiving an ABO-compatible donor liver.
authors.affiliation: Department of Medicine, Rikshospitalet, Oslo, Norway. kristian.bjoro@labmed.uio.no.
authors.forename: K
authors.initials: K
authors.lastname: Bjøro
authors.forename: B G
authors.initials: BG
authors.lastname: Ericzon
authors.forename: P
authors.initials: P
authors.lastname: Kirkegaard
authors.forename: K
authors.initials: K
authors.lastname: Höckerstedt
authors.forename: G
authors.initials: G
authors.lastname: Söderdahl
authors.forename: M
authors.initials: M
authors.lastname: Olausson
authors.forename: A
authors.initials: A
authors.lastname: Foss
authors.forename: L E
authors.initials: LE
authors.lastname: Schmidt
authors.forename: H
authors.initials: H
authors.lastname: Isoniemi
authors.forename: B
authors.initials: B
authors.lastname: Brandsaeter
authors.forename: S
authors.initials: S
authors.lastname: Friman
mesh_terms: D000017:ABO Blood-Group System; D000082:Acetaminophen / Q000506:poisoning; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000506:poisoning; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D005260:Female; D006085:Graft Survival; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000401:mortality / Q000601:surgery; D006801:Humans; D017093:Liver Failure / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012086:Reoperation; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System; D018712:Analgesics, Non-Narcotic; D000082:Acetaminophen